Actively Recruiting
Translocator Protein PET/CT in Various TSPO-Related Disease
Led by Tianjin Medical University · Updated on 2025-02-11
200
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
Sponsors
T
Tianjin Medical University
Lead Sponsor
T
Tianjin Medical University General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the potential usefulness of 18F-DPA714/FDPA positron emission tomography/computed tomography (PET/CT) for diagnosing primary and metastatic lesions in patients with various TSPO-related diseases, including neuroinflammation, stroke, and neurodegenerative diseases. This observational study aims to assess the accuracy of this imaging method by measuring lesion uptake and calculating diagnostic values like sensitivity and specificity. Participants receive a single intravenous injection of 18F-DPA714/FDPA and then undergo PET/CT or MRI imaging within a specified timeframe. The study focuses on quantifying lesion uptake using the maximum standardized uptake value (SUVmax) to evaluate the diagnostic performance of the imaging technique. During the study, researchers measure the standardized uptake value within 30 days and assess diagnostic efficacy as a secondary outcome. Participants provide informed consent and may include adults aged 18 to 80 years with suspected or diagnosed malignant tumors scheduled for TSPO PET/CT scans. The total involvement duration is around 30 days, with imaging and data analysis conducted during this period.
CONDITIONS
Brief Title
Translocator Protein PET/CT in Various TSPO-Related Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Patients with suspected, newly diagnosed, or previously treated malignant tumors supported by MRI, CT, tumor markers, or pathology reports
- Patients scheduled for TSPO PET/CT scan
- Patients able to provide informed consent and assent according to ethics guidelines
You will not qualify if you...
- Patients with non-malignant lesions
- Pregnant patients
- Patients unable or unwilling to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants receive a single intravenous injection of 18F-DPA714/FDPA and undergo PET/CT or MRI imaging to assess lesions related to TSPO diseases.
1 visit (in-person)
Duration - 30 days
Participants are monitored for up to 30 days to evaluate the standardized uptake value (SUV) and diagnostic efficacy of the imaging.
Follow-up assessments as needed
Trial Site Locations
Total: 2 locations
1
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China, 230000
Actively Recruiting
2
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China, 300052
Actively Recruiting
Research Team
Y
Ying Wang
L
Li Cai, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here